**Table S5. Sensitivity analysis on ORT effectiveness parameters. Incremental cost-effectiveness ratio ($/QALY gained) for selected strategies on the efficient frontier compared to the next-best strategy.\***

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Variable** |  **Anti-HIV, Upon entry to ORT**  | **Anti-HIV, Annual** | **Anti-HIV, 6 months** | **Anti-HIV+RNA, Upon entry to ORT** | **Anti-HIV+RNA, Annual** | **Anti-HIV+RNA, 6 months** | **Anti-HIV+RNA, 3 months** | **Anti-HIV+RNA, 3 months; Anti-HCV, Upon entry to ORT**  |
| **BASE CASE** | **11,191** | **20,075** | **30,713** | **33,503** | **44,141** | **65,883** | **115,429** | **168,600** |
| **Effectiveness of ORT, Transition from IDU in ORT to non-IDU (base case: 1.8% per year)** |  |  |  |  |  |  |  |  |
| Lower, 0.9% per year |  11,037  |  20,031  |  30,770  |  33,048  |  44,092  |  65,815  |  115,458  |  175,645  |
| Higher, 3.6% per year  |  11,489  |  20,160  |  30,603  |  34,364  |  44,236  |  66,016  |  115,367  |  156,699  |
| **Average time in ORT (base case:1.5 years)** |  |  |  |  |  |  |  |  |
| Shorter ORT duration 1.0 years |  10,470  |  18,715  |  27,109  |  29,330  |  43,489  |  63,042  |  107,487  |  229,679  |
| Longer ORT duration, 2.25 years |  11,856  |  21,273  |  34,012  | Dominated |  45,936  |  68,588  |  122,286  |  138,264  |

 \*“Dominated” indicates that the strategy costs more and provides fewer QALYs than another strategy or a combination of two strategies (called “Extended Dominance”).